Algethami, M., Shoqafi, A., Lashen, A., Alqahtani, S., Spicer, J., ALtayyar, A., . . . Madhusudan, S. Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities. Nature Portfolio.
Chicago Style (17th ed.) CitationAlgethami, Mashael, et al. Investigation of Ribociclib, Abemaciclib and Palbociclib Resistance in ER+ Breast Cancer Cells Reveal Potential Therapeutic Opportunities. Nature Portfolio.
MLA (9th ed.) CitationAlgethami, Mashael, et al. Investigation of Ribociclib, Abemaciclib and Palbociclib Resistance in ER+ Breast Cancer Cells Reveal Potential Therapeutic Opportunities. Nature Portfolio.
Warning: These citations may not always be 100% accurate.